-
Inventory of indications and adverse reactions of domestic immunotherapy drug camrelizumab!
Time of Update: 2022-05-25
Today, we will take stock of the approved indications, adverse reactions and treatment measures of camrelizumab .
Today, we will take stock of the approved indications, adverse reactions and treatment measures of camrelizumab .
-
European Radiology: Radiomics nomogram to identify IDH mutations and loss of ATRX expression in low-grade gliomas
Time of Update: 2022-05-25
In conclusion, a nomogram combining age, gender, and radiomic features provides a non-invasive imaging method for predicting IDH and ATRX mutations in LrGG patients, which can assist in the development of personalized treatment plans .
-
AACR 2022: Progress of innovative drugs under development for TSLP targets
Time of Update: 2022-05-22
Globally, AstraZeneca/Amgen's Tezepelumab, a giant company with the most advanced TSLP monoclonal antibody drug development progress, was approved for marketing in the United States on December 17, 2021, and Phase 3 clinical studies have been launched in China .
-
JCO: Digital Breast Cancer Course Management Based on Electronic Patient-Reported Outcome (ePRO) Monitoring and Automated Management of Intervention Reminders (eRAPID Study)
Time of Update: 2022-05-22
The eRAPID system combines ePRO symptom reporting with customized clinical algorithms to provide patients with automated, severity-based recommendations to support patients in self-management or contacting the hospital .
-
Major milestone: The third-generation ALK inhibitor lorlatinib, an innovative lung cancer drug, was approved in China
Time of Update: 2022-05-22
On April 29 , 2022 , Pfizer announced that the world's first third-generation ALK inhibitor Borrena® ( Lorbrena® , generic name: Lorlatinib Tablets ) was approved by the State Drug Administration for single drug use for the treatment of patients with anaplastic lymphoma kinase ( ALK )-positive locally advanced or metastatic non-small cell lung cancer ( NSCLC ) .
-
Anti-Nucleotide Metabolism Enhances Anticancer Immune Efficacy
Time of Update: 2022-05-22
On April 27, 2022, the Journal of Hematology and Oncology, a subsidiary of the British Biomedical Center, published online a long review of scholars such as Wu Huailiang, Gong Yue, Ji Peng, Xie Yifan, Jiang Yizhou, Liu Guangyu and other scholars from the Cancer Hospital of Fudan University.
-
Cancer Res: Chemotherapy combined with macrophages inhibits progression of triple-negative breast cancer
Time of Update: 2022-05-22
gov/35442423/Recently, researchers at Baylor College of Medicine published an article titled "Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer" in the journal Cancer research.
-
Lancet Oncol: 10-year follow-up results of high-dose radiotherapy plus long-term androgen deprivation therapy for prostate cancer
Time of Update: 2022-05-21
The 5-year follow-up showed that 2 years of adjuvant androgen deprivation combined with high-dose radiotherapy significantly improved biochemical control, metastasis, and overall survival in patients, especially in high-risk patients .
-
NICE recommends Bavncio (avelumab) for locally advanced metastatic urothelial carcinoma (UC)
Time of Update: 2022-05-21
4% in the control group (median overall survival, 21.
4% in the control group (median overall survival, 21.
4% in the control group (median overall survival, 21.
-
J Clin Oncol: The MEK inhibitor Selumetinib in the treatment of malignant tumors with MAPK pathway mutations
Time of Update: 2022-05-21
However, selumetinib had limited efficacy in refractory tumors harboring MAPK mutations in this cohort, suggesting that this pathway mutation status alone is not sufficient to predict response to selumetinib monotherapy in pediatric patients with malignancy .
-
BeiGene's tislelizumab is approved again in China
Time of Update: 2022-05-21
BeiGene announced today that China’s drug regulator has expanded the approval of tislelizumab to include patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) with progressive disease or intolerant to first-line chemotherapy .
-
2022CSCO Prof. Yin Yongmei: 3 major update points of HER-2 positive breast cancer diagnosis and treatment guidelines
Time of Update: 2022-05-21
In this article, Professor Yin Yongmei from Jiangsu Provincial People's Hospital explained in detail the updated key points of neoadjuvant therapy, adjuvant therapy and the treatment of HER-2 positive recurrent and metastatic breast cancer in the guidelines for the diagnosis and treatment of HER-2 positive breast cancer .
-
The reason why "Old Smoking Gun" does not suffer from lung cancer has been found!
Time of Update: 2022-05-21
" One pack of cigarettes a day, happy like a fairy " is a realistic portrayal of many old smokers . Smoking may be for relieving anxiety and tension, for socializing to gain acceptance in the group,
-
NEJM: Nivolumab plus chemotherapy as neoadjuvant therapy for resectable lung cancer can greatly improve patient outcomes
Time of Update: 2022-05-21
For patients with resectable non-small cell lung cancer, compared with chemotherapy alone, nivolumab combined with chemotherapy neoadjuvant therapy can significantly prolong event-free survival, significantly increase the rate of pathological complete response, and do not increase the incidence of adverse events .
-
Cancer Discovery: Yu Dihua's team found that vitamin E can improve the survival rate of cancer patients, and enhance the effect of cancer immunotherapy by activating dendritic cells
Time of Update: 2022-05-21
Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1Combining retrospective analysis of clinical records with laboratory studies, the research team found that vitamin E directly binds and blocks the immune checkpoint protein SHP1 in dendritic cells, thereby activating dendritic cell activity, enhancing antigen presentation and priming T cells.
-
A pack of cigarettes a day is better than a living fairy?
Time of Update: 2022-05-21
It's worth noting that this study isn't suggesting that more smoking is associated with a lower risk of cancer -- all smokers had a higher number of somatic mutations and a greater risk of lung cancer than non-smokers .
-
NICE recommends Merck's Tepmetko (tepotinib) for lung cancer
Time of Update: 2022-05-21
Lung cancerNSCLCTepotinib is the first and only oral MET inhibitor recommended for the treatment of adult patients with advanced NSCLC with a METex14 skipping mutation for the NHS in England, Wales and Northern Ireland .
-
Cell: Heavy!
Time of Update: 2022-05-21
ovarian cancer"These smart cell therapies can deliver powerful therapeutic activity precisely at the site of disease, improving efficacy and reducing the chance of life-threatening toxicity in patients," Roybal said .
-
Science Cover: Amazing!
Time of Update: 2022-05-21
Well, I think everyone should realize that this study is to verify that ESCRT is also involved in cancer cells repairing membrane damage caused by T-cell perforin, and the verification should be successful.
-
Radiology: Imaging and pathologically relevant signs suggestive of low nuclear grade DCIS
Time of Update: 2022-05-21
(B) US image shows a 7 mm isoechoic microspheroid nodule located at 12 o'clock in the right breast, 3 cm from the nipple (arrow)The present study showed that the rate of escalation of low nuclear grade carcinoma in situ (DCIS) at biopsy to moderate to high grade at surgery was 38.